A Randomised Phase II Study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2017
At a glance
- Drugs Nintedanib (Primary) ; Carboplatin; Doxorubicin; Doxorubicin liposomal; Paclitaxel; Topotecan
- Indications Endometrial cancer; Ovarian cancer
- Focus Therapeutic Use
- Acronyms NiCCC
- 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 11 Dec 2015 According to United Kingdom Clinical Research Network record accrual to date is 5%.
- 05 Nov 2015 According to United Kingdom Clinical Research Network record accrual to date is 4%.